Literature DB >> 9584045

Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report.

N Viñolas1, R Molina, M C Galán, F Casas, M A Callejas, X Filella, J J Grau, A M Ballesta, J Estape.   

Abstract

BACKGROUND: The significance of tumor markers in lung cancer is not well established. PATIENTS AND METHODS: We analyzed level of serum markers as prognostic factor of response and survival in 46 evaluable patients with locally advanced or metastasic non small cell lung cancer. All patients were treated with cisplatin 120 mg/m2 or carboplatin 400 mg/m2 day 1, plus etoposide 80 mg/m2 days 1 to 3.
RESULTS: Partial response was obtained in 11 patients (24%), stabilization in 18 and progression in 17. Tumor marker sensitivities were: CEA 37%, CA 125 54.5%, SCC 17.5%, NSE 30.5%, and CYFRA 52%. Higher levels of CEA and NSE correlated with more probability of response (p < 0.001 and p = 0.002). The survival probability of patients with normal pretreatment levels of NSE was significantly better than those with NSE over normal level (15.2 vs 7.2 months) p = 0.02. In patients who achieved partial response, CEA, CA 125 and CYFRA levels decreased significantly with respect to the pretreatment values.
CONCLUSIONS: Patients with high CEA and NSE serum level have an increased probability of response than patients with low initial levels; however, patients with high initial level of NSE have poor survival. The decrease in CEA, CA 125 and CYFRA values at the moment of response evaluation could help in response assessment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584045

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib.

Authors:  Minehiko Inomata; Ryuji Hayashi; Azusa Yamamoto; Kotaro Tokui; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Kensuke Suzuki; Tomomi Ichikawa; Toru Yamada; Toshiro Miwa; Tatsuhiko Kashii; Shoko Matsui; Kazuyuki Tobe; Johji Imura
Journal:  Mol Clin Oncol       Date:  2015-05-14

2.  Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 Binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer.

Authors:  Lichao Sun; Lizhao Chen; Lixin Sun; Jian Pan; Long Yu; LuLu Han; Zhihua Yang; Yuanming Luo; Yuliang Ran
Journal:  Mol Cell Proteomics       Date:  2012-11-26       Impact factor: 5.911

3.  Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer.

Authors:  Akihiro Yoshimura; Junji Uchino; Koichi Hasegawa; Taisuke Tsuji; Shinsuke Shiotsu; Tatsuya Yuba; Chieko Takumi; Tadaaki Yamada; Koichi Takayama; Noriya Hiraoka
Journal:  Transl Lung Cancer Res       Date:  2019-06

4.  The prognostic value of carcinoembryonic antigen levels in blood and intraoperative pleural lavage fluid in non-small-cell lung cancer.

Authors:  Tevfik Ilker Akcam; Ufuk Cagirici; Ayse Gul Ergonul; Ali Ozdil; Onder Kavurmaci; Kutsal Turhan; Alpaslan Cakan; Burcu Barutcuoglu
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-06-30

5.  The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer.

Authors:  Linjie Liu; Jinlong Teng; Lijun Zhang; Peishan Cong; Yuan Yao; Guirong Sun; Zhijun Liu; Teng Yu; Mingjun Liu
Journal:  Biomed Res Int       Date:  2017-05-18       Impact factor: 3.411

6.  Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis.

Authors:  Zhineng Wen; Ying Huang; Zhougui Ling; Jifei Chen; Xiaomou Wei; Rui Su; Zhenming Tang; Zhongwei Wen; Youping Deng; Zhuojun Hu
Journal:  Dis Markers       Date:  2020-12-10       Impact factor: 3.434

7.  Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer.

Authors:  Rong Wang; Guoqing Wang; Nan Zhang; Xue Li; Yunde Liu
Journal:  Biomed Res Int       Date:  2013-09-19       Impact factor: 3.411

8.  The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types.

Authors:  Haiqing Chen; Fangqiu Fu; Yue Zhao; Haoxuan Wu; Hong Hu; Yihua Sun; Yawei Zhang; Jiaqing Xiang; Yang Zhang
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.